同种异体心脏干细胞冠状动脉内输注促进心肌再生(ALLSTAR):随机安慰剂对照双盲试验
ALLSTAR试验在心肌梗死后4周至12个月、LVEF≤45%且瘢痕≥15%的患者中,比较冠状动脉内输注同种异体心脏来源细胞(CDC)与安慰剂的安全性和有效性。因中期分析显示主要终点显著获益可能性低而提前终止;6个月时CDC未减少瘢痕面积,但降低左室容积和NT-proBNP。
要点
- 同种异体CDC冠状动脉内输注在心肌梗死后左室功能不全患者中安全。
- 6个月时CDC组与安慰剂组瘢痕面积变化无显著差异。
- CDC组左室舒张末容积、收缩末容积和NT-proBNP较安慰剂组显著降低。
核心结论
- 心肌梗死后左室功能不全患者冠状动脉内输注同种异体CDC安全,但6个月时未较安慰剂减少瘢痕面积。
- 左室容积和NT-proBNP的降低提示CDC具有疾病修饰生物活性。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验(ALLSTAR),入组心肌梗死后4周至12个月、LVEF≤45%且MRI示瘢痕≥15%左室质量的患者。
- 按2:1随机分配接受CDC或安慰剂,经停流技术注入梗死相关动脉;共随机142例,治疗134例(CDC组90例,安慰剂组44例)。
- 预设中期分析基于6个月MRI数据,因主要终点显著治疗效应检出概率低而终止试验。
主要发现
- 基线平均LVEF为40%,平均瘢痕大小为左室质量的22%。
- 未发生主要安全性终点事件。
- 6个月时瘢痕面积相对基线变化百分比在CDC组与安慰剂组间无差异(P=0.51)。
- 6个月时CDC组左室舒张末容积(P=0.02)、左室收缩末容积(P=0.02)和NT-proBNP(P=0.02)较安慰剂组显著降低。
关键数值与推荐
- 主要安全性终点为输注后1个月内发生归因于同种异体CDC的急性心肌炎、室速/室颤相关死亡、猝死或主要不良心脏事件(死亡、心衰住院、非致死性心梗、需左室辅助装置或心脏移植)。
- 主要有效性终点为输注后12个月对比增强心脏MRI评估的梗死面积相对百分比变化。
临床怎么用
- 同种异体CDC冠状动脉内输注在该人群中安全性良好,但未显著减少瘢痕面积,不宜以减少瘢痕为主要目的应用。
- 左室容积和NT-proBNP的降低提示潜在疾病修饰作用,需进一步研究确认临床获益。
局限性
- 试验因中期分析显示主要终点显著获益可能性低而提前终止。
- 样本量有限(治疗134例),可能影响次要终点和亚组分析的把握度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Cardiosphere-derived cells (CDCs) are cardiac progenitor cells that exhibit disease-modifying bioactivity in various models of cardiomyopathy and in previous clinical studies of acute myocardial infarction (MI), dilated cardiomyopathy, and Duchenne muscular dystrophy. The aim of the study was to assess the safety and efficacy of intracoronary administration of allogeneic CDCs in the multicentre, randomized, double-blinded, placebo-controlled, intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR) trial. METHODS AND RESULTS: We enrolled patients 4 weeks to 12 months after MI, with left ventricular ejection fraction (LVEF) ≤45% and LV scar size ≥15% of LV mass by magnetic resonance imaging (MRI). A pre-specified interim analysis was performed when 6-month MRI data were available. The trial was subsequently stopped due to the low probability of detecting a significant treatment effect of CDCs based on the primary endpoint. Patients were randomly allocated in a 2:1 ratio to receive CDCs or placebo in the infarct-related artery by stop-flow technique. The primary safety endpoint was the occurrence, during 1-month post-intracoronary infusion, of acute myocarditis attributable to allogeneic CDCs, ventricular tachycardia- or ventricular fibrillation-related death, sudden unexpected death, or a major adverse cardiac event (death or hospitalization for heart failure or non-fatal MI or need for left ventricular assist device or heart transplant). The primary efficacy endpoint was the relative percentage change in infarct size at 12 months post-infusion as assessed by contrast-enhanced cardiac MRI. We randomly allocated 142 eligible patients of whom 134 were treated (90 to the CDC group and 44 to the placebo group). The mean baseline LVEF was 40% and the mean scar size was 22% of LV mass. No primary safety endpoint events occurred. There was no difference in the percentage change from baseline in scar size (P = 0.51) between CDCs and placebo groups at 6 months. Compared with placebo, there were significant reductions in LV end-diastolic volume (P = 0.02), LV end-systolic volume (P = 0.02), and N-terminal pro b-type natriuretic peptide (NT-proBNP) (P = 0.02) at 6 months in CDC-treated patients. CONCLUSION: Intracoronary infusion of allogeneic CDCs in patients with post-MI LV dysfunction was safe but did not reduce scar size relative to placebo at 6 months. Nevertheless, the reductions in LV volumes and NT-proBNP reveal disease-modifying bioactivity of CDCs. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01458405.
引用
- Makkar RR, Kereiakes DJ, Aguirre F, et al. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2020. PMID: 32749459. doi:10.1093/eurheartj/ehaa541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。